recurrent ovarian cancer

June 22, 2018June 22, 2018

A Second Surgery Can Improve Survival for Women with Recurring Ovarian Cancer, Study Shows

News

Follow-up surgery to remove all traces of cancer can improve the survival of women whose ovarian cancer returned after initial surgery and chemotherapy, a Norwegian study shows. In the study, ... Read more

May 21, 2018

Update on Apealea, Potential Ovarian Cancer Therapy, Set for ASCO 2018 in June

News

Apealea, a water-soluble formulation of the chemotherapy paclitaxel, is not inferior to the standard formulation, Taxol (cremophor- EL paclitaxel), and may even improve the survival of ovarian cancer patients who responded to platinum-based ... Read more

April 30, 2018

Zejula Shows Ability to Treat Range of Advanced Ovarian Cancers in Phase 2 Trial

News

Zejula (niraparib) showed an ability to treat people with recurrent and heavily treated ovarian cancer, particularly those with mutations in DNA repairing genes, results of a Phase 2 trial show. Tesaro’s ... Read more

November 15, 2017November 15, 2017

OncoQuest, Tesaro Team Up to Test Oregovomab-Zejula Combo

News

OncoQuest has entered into a collaborative agreement with Tesaro to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab (MAb B43.13) with Zejula (niraparib) in recurrent ovarian cancer. Oregovomab is ... Read more

September 6, 2017

Phase 1 Clinical Trial Is Assessing Cantrixil in Ovarian Cancer Patients Who Are Resistant to Chemo

News

Three Australian and two American cancer centers are spearheading the first clinical trial of Cantrixil, Novogen’s therapy to restore ovarian cancer patients’ sensitivity to chemotherapy. Associate Professor Jim Coward, an oncologist at ... Read more

March 17, 2017March 17, 2017

Ovarian Cancer Patients Benefit from Lynparza Maintenance Tablets, Trial Suggests

News

Ovarian cancer patients who have an inherited BRCA mutation, and who responded to platinum-based chemotherapy, benefit from using Lynparza (olaparib) tablets as a maintenance treatment, a clinical trial suggests. The ... Read more

December 21, 2016

Phase 2 Trial Suggests TTFields-Chemotherapy Combo May Improve Outcomes in Recurrent Ovarian Cancer

News

Combining Tumor Treating Fields (TTFields), a method that uses electric fields to disrupt cell division, with Taxol (paclitaxel) may be a promising treatment approach for ovarian cancer patients, according to recent ... Read more